{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:26:34Z","timestamp":1772810794802,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thyroid Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dysthyroid Optic Neuropathy (DON) is a sight-threatening complication of Thyroid Eye Disease (TED). This study aims to identify the risk and predictive factors for DON in a multi-ethnic TED cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective, cohort study of consecutive TED patients attending a multidisciplinary service over an 11-year period. Consecutive patients aged over 18 years old with a minimum of 6 months follow-up post-diagnosis of TED were included. We compared those patients with DON and those without (no-DON) to determine which factors were more prevalent in patients with DON.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 26 and 516 consecutive patients with DON and no-DON. The DON prevalence in the cohort was 5.0%. The DON group had a Mean Age at TED Diagnosis (MATD) of 57.8 vs. 46.1 years in the no-DON group. The mean presenting CAS, TRAb and Gorman Diplopia Score (GDS) were significantly higher 3.73\u2009\u00b1\u20091.80, 2.76\u2009\u00b1\u20091.05 and 11.31\u2009\u00b1\u200911.90 vs. 0.54\u2009\u00b1\u20090.80, 0.48\u2009\u00b1\u20090.90 and 6.95\u2009\u00b1\u20099.22 in the DON compared to the no-DON group respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). On multivariable regression, we found the following risk factors for developing DON (Odds Ratios): MATD\u2009\u2265\u200953 years (5.2\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00), presenting CAS\u2009\u2265\u20094 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.00), presenting GDS\u2009\u2265\u20093 (7.5\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00), diabetes (5.7\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00), and baseline TRAb\u2009\u2265\u20095.0 IU\/L (2.9\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with diabetes, increased MATD, and high presenting CAS, GDS, and TRAb are at increased risk of developing DON in our cohort. Clinicians should be especially vigilant of the risk of sight-threatening complications in TED patients with more than one of the above risk factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13044-025-00249-4","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T23:08:25Z","timestamp":1753139305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive demographic and clinical features for the development of dysthyroid optic neuropathy in a multi-ethnic TED population: a retrospective cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Malik","family":"Moledina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vickie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Alnahrawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ourania","family":"Fydanaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nour","family":"Hubby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy","family":"Metcalf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Akshikar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajni","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassiliki","family":"Bravis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Meeran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"4","key":"249_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/cen.14296","volume":"93","author":"YH Chin","year":"2020","unstructured":"Chin YH, Ng CH, Lee MH, Koh JWH, Kiew J, Yang SP, et al. Prevalence of thyroid eye disease in graves\u2019 disease: A meta-analysis and systematic review. Clin Endocrinol (Oxford). 2020;93(4):363\u201374. https:\/\/doi.org\/10.1111\/cen.14296.","journal-title":"Clin Endocrinol (Oxford)"},{"issue":"1","key":"249_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ajo.2006.02.047","volume":"142","author":"JA Garrity","year":"2006","unstructured":"Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol. 2006;142(1):147\u2013e1532. https:\/\/doi.org\/10.1016\/j.ajo.2006.02.047.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"249_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/17469899.2017.1276444","volume":"12","author":"AD Blandford","year":"2017","unstructured":"Blandford AD, Zhang D, Chundury RV, Perry JD. Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol. 2017;12(2):111\u201321. https:\/\/doi.org\/10.1080\/17469899.2017.1276444.","journal-title":"Expert Rev Ophthalmol"},{"issue":"10","key":"249_CR4","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1089\/105072502761016476","volume":"12","author":"WM Wiersinga","year":"2002","unstructured":"Wiersinga WM, Bartalena L. Epidemiology and prevention of graves\u2019 ophthalmopathy. Thyroid. 2002;12(10):855\u201360. https:\/\/doi.org\/10.1089\/105072502761016476.","journal-title":"Thyroid"},{"issue":"10","key":"249_CR5","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s41433-018-0144-x","volume":"32","author":"Y Wong","year":"2018","unstructured":"Wong Y, Dickinson J, Perros P, Dayan C, Veeramani P, Morris D, et al. A British ophthalmological surveillance unit (BOSU) study into dysthyroid optic neuropathy in the united Kingdom. Eye (London). 2018;32(10):1555\u201362. https:\/\/doi.org\/10.1038\/s41433-018-0144-x.","journal-title":"Eye (London)"},{"issue":"12","key":"249_CR6","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.4103\/ijo.IJO_719_22","volume":"70","author":"N Poonam","year":"2022","unstructured":"Poonam N, Alam M, Oberoi P, Mukherjee B. Dysthyroid optic neuropathy: demographics, risk factors, investigations, and management outcomes. Indian J Ophthalmol. 2022;70(12):4419\u201326. https:\/\/doi.org\/10.4103\/ijo.IJO_719_22.","journal-title":"Indian J Ophthalmol"},{"key":"249_CR7","doi-asserted-by":"crossref","unstructured":"Khong JJ, Finch S, De Silva C, Rylander S, Craig JE, Selva D, et al. Risk factors for graves\u2019 orbitopathy; the Australian Thyroid-Associated orbitopathy research (ATOR) study. J Clin Endocrinol Metab. 2016;101(7):2711\u201320. https:\/\/doi.org\/10.1210\/jc.2015\u20134294.","DOI":"10.1210\/jc.2015-4294"},{"key":"249_CR8","doi-asserted-by":"publisher","unstructured":"Kemchoknatee P, Thongsawangchai N, Srisombut T, Tangon D, Chantra S. Predictive factors of development of dysthyroid optic neuropathy among individuals with thyroid-eye disease. Eur J Ophthalmol. 2023;11206721231199868. https:\/\/doi.org\/10.1177\/11206721231199868.","DOI":"10.1177\/11206721231199868"},{"issue":"2","key":"249_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","volume":"16","author":"RS Bahn","year":"1987","unstructured":"Bahn RS, Gorman CA. Choice of therapy and criteria for assessing treatment outcome in Thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am. 1987;16(2):391\u2013407. https:\/\/doi.org\/10.1016\/S0889-8529(18)30485-7.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"249_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with graves\u2019 ophthalmopathy. Clin Endocrinol (Oxford). 1997;47(1):9\u201314. https:\/\/doi.org\/10.1046\/j.1365-2265.1997.2331047.x.","journal-title":"Clin Endocrinol (Oxford)"},{"issue":"3","key":"249_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","volume":"54","author":"CB Terwee","year":"2001","unstructured":"Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, et al. Interpretation and validity of changes in scores on the graves\u2019 ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxford). 2001;54(3):391\u20138. https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01241.x.","journal-title":"Clin Endocrinol (Oxford)"},{"issue":"4","key":"249_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/bjo.2006.110932","volume":"91","author":"CM Dayan","year":"2007","unstructured":"Dayan CM, Dayan MR. Dysthyroid optic neuropathy: a clinical diagnosis or a definable entity? Br J Ophthalmol. 2007;91(4):409\u201310. https:\/\/doi.org\/10.1136\/bjo.2006.110932.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"249_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.6061\/clinics\/2012(11)18","volume":"67","author":"ACP Gon\u00e7alves","year":"2012","unstructured":"Gon\u00e7alves ACP, Gebrim EMMS, Monteiro MLR. Imaging studies for diagnosing graves\u2019 orbitopathy and dysthyroid optic neuropathy. Clinics (S\u00e3o Paulo Brazil). 2012;67(11):1327\u201334. https:\/\/doi.org\/10.6061\/clinics\/2012(11)18.","journal-title":"Clinics (S\u00e3o Paulo Brazil)"},{"issue":"4","key":"249_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/01676830.2017.1314510","volume":"36","author":"CJ Choi","year":"2017","unstructured":"Choi CJ, Oropesa S, Callahan AB, Glass LR, Teo L, Cestari DM, et al. Patterns of visual field changes in thyroid eye disease. Orbit (Amsterdam). 2017;36(4):201\u20137. https:\/\/doi.org\/10.1080\/01676830.2017.1314510.","journal-title":"Orbit (Amsterdam)"},{"issue":"2","key":"249_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/01676830.2019.1600150","volume":"39","author":"VS Starks","year":"2020","unstructured":"Starks VS, Reinshagen KL, Lee NG, Freitag SK. Visual field and orbital computed tomography correlation in dysthyroid optic neuropathy due to thyroid eye disease. Orbit. 2020;39(2):77\u201383. https:\/\/doi.org\/10.1080\/01676830.2019.1600150.","journal-title":"Orbit"},{"issue":"4S Suppl 1","key":"249_CR16","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1097\/IOP.0000000000001128","volume":"34","author":"AB Callahan","year":"2018","unstructured":"Callahan AB, Campbell AA, Oropesa S, Baraban A, Kazim M. The Columbia thyroid eye Disease-Compressive optic neuropathy diagnostic formula. Ophthal Plast Reconstr Surg. 2018;34(4S Suppl 1):S68\u201371. https:\/\/doi.org\/10.1097\/IOP.0000000000001128.","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"4","key":"249_CR17","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European group on graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185(4):G43\u201367. https:\/\/doi.org\/10.1530\/EJE-21-0479.","journal-title":"Eur J Endocrinol"},{"key":"249_CR18","doi-asserted-by":"publisher","unstructured":"Moledina M, Lee V, Bhatia K. Radiological activity score (RAS)-MRI characteristics in dysthyroid optic neuropathy in a multi-ethnic thyroid eye disease population. Clin Endocrinol (Oxf). 2025. https:\/\/doi.org\/10.1111\/cen.15272.","DOI":"10.1111\/cen.15272"},{"issue":"7","key":"249_CR19","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1001\/archopht.1978.03910060033007","volume":"96","author":"JD Trobe","year":"1978","unstructured":"Trobe JD, Glaser JS, Laflamme P. Dysthyroid optic neuropathy: clinical profile and rationale for management. Archives Ophthalmol (1960). 1978;96(7):1199\u2013209. https:\/\/doi.org\/10.1001\/archopht.1978.03910060033007.","journal-title":"Archives Ophthalmol (1960)"},{"issue":"12","key":"249_CR20","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00417-015-3156-2","volume":"253","author":"GJ Ben Simon","year":"2015","unstructured":"Ben Simon GJ, Katz G, Zloto O, Leiba H, Hadas B, Huna-Baron R. Age differences in clinical manifestation and prognosis of thyroid eye disease. Graefe\u2019s Archive Clin Experimental Ophthalmol. 2015;253(12):2301\u20138. https:\/\/doi.org\/10.1007\/s00417-015-3156-2.","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol"},{"issue":"1","key":"249_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3390\/jcm13010290","volume":"13","author":"M Oeverhaus","year":"2024","unstructured":"Oeverhaus M, Sander J, Smetana N, Bechrakis NE, Inga N, Al-Ghazzawi K, et al. How age affects graves\u2019 Orbitopathy\u2014A tertiary center study. J Clin Med. 2024;13(1):290. https:\/\/doi.org\/10.3390\/jcm13010290.","journal-title":"J Clin Med"},{"issue":"4","key":"249_CR22","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/IOP.0000000000001871","volume":"37","author":"S Rath","year":"2021","unstructured":"Rath S, Pattnaik M, Tripathy D, Mohapatra S, Panigrahy B, Ali MH. Sight-Threatening thyroid eye disease: role of diabetes mellitus and interaction with other risk factors. Ophthal Plast Reconstr Surg. 2021;37(4):352\u201360. https:\/\/doi.org\/10.1097\/IOP.0000000000001871.","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"6","key":"249_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.4103\/ijo.IJO_1443_19","volume":"68","author":"L Ramamurthy","year":"2020","unstructured":"Ramamurthy L, Rangarajan V, Srirao N, Malini B, Bansal R, Yuvarajan K. Severity of thyroid eye disease and type-2 diabetes mellitus: is there a correlation? Indian J Ophthalmol. 2020;68(6):1127\u201331. https:\/\/doi.org\/10.4103\/ijo.IJO_1443_19.","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"249_CR24","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.4103\/ijo.IJO_2284_19","volume":"68","author":"R Gupta","year":"2020","unstructured":"Gupta R, Thomas R, Almukhtar F, Kiran A. Visual morbidity in thyroid eye disease in Asian Indian patients. Indian J Ophthalmol. 2020;68(8):1622\u20137. https:\/\/doi.org\/10.4103\/ijo.IJO_2284_19.","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"249_CR25","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.4103\/ijo.IJO_104_20","volume":"68","author":"A Muralidhar","year":"2020","unstructured":"Muralidhar A, Das S, Tiple S. Clinical profile of thyroid eye disease and factors predictive of disease severity. Indian J Ophthalmol. 2020;68(8):1629\u201334. https:\/\/doi.org\/10.4103\/ijo.IJO_104_20.","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"249_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3341\/kjo.2012.26.2.73","volume":"26","author":"C Jeon","year":"2012","unstructured":"Jeon C, Shin JH, Woo KI, Kim Y. Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy. Korean J Ophthalmology: KJO. 2012;26(2):73\u20139. https:\/\/doi.org\/10.3341\/kjo.2012.26.2.73.","journal-title":"Korean J Ophthalmology: KJO"},{"key":"249_CR27","doi-asserted-by":"publisher","first-page":"959276","DOI":"10.3389\/fendo.2022.959276","volume":"13","author":"R Le Moli","year":"2022","unstructured":"Le Moli R, Vella V, Tumino D, Piticchio T, Naselli A, Belfiore A, et al. Inflammasome activation as a link between obesity and thyroid disorders: implications for an integrated clinical management. Front Endocrinol (Lausanne). 2022;13:959276. https:\/\/doi.org\/10.3389\/fendo.2022.959276.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"249_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/bjo.83.4.463","volume":"83","author":"R Kalmann","year":"1999","unstructured":"Kalmann R, Mourits MP. Diabetes mellitus: a risk factor in patients with graves\u2019 orbitopathy. Br J Ophthalmol. 1999;83(4):463\u20135. https:\/\/doi.org\/10.1136\/bjo.83.4.463.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"249_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40618-019-01126-2","volume":"43","author":"S Rosetti","year":"2020","unstructured":"Rosetti S, Tanda ML, Veronesi G, Masiello E, Premoli P, Gallo D, et al. Oral steroid prophylaxis for graves\u2019 orbitopathy after radioactive iodine treatment for graves\u2019 disease is not only effective, but also safe. J Endocrinol Investig. 2020;43(3):381\u20133. https:\/\/doi.org\/10.1007\/s40618-019-01126-2.","journal-title":"J Endocrinol Investig"},{"issue":"4","key":"249_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/bjo.2006.094607","volume":"91","author":"D McKeag","year":"2007","unstructured":"McKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ, et al. Clinical features of dysthyroid optic neuropathy: a European group on graves\u2019 orbitopathy (EUGOGO) survey. Br J Ophthalmol. 2007;91(4):455\u20138. https:\/\/doi.org\/10.1136\/bjo.2006.094607.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"249_CR31","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1097\/IOP.0000000000001147","volume":"34","author":"JM Uddin","year":"2018","unstructured":"Uddin JM, Rubinstein T, Hamed-Azzam S. Phenotypes of thyroid eye disease. Ophthal Plast Reconstr Surg. 2018;34(4):S28\u201333. https:\/\/doi.org\/10.1097\/IOP.0000000000001147.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"249_CR32","doi-asserted-by":"crossref","unstructured":"Eckstein AK, Plicht M, Lax H, Neuh\u00e4user M, Mann K, Lederbogen S, et al. Thyrotropin receptor autoantibodies are independent risk factors for graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91(9):3464\u201370. https:\/\/doi.org\/10.1210\/jc.2005\u20132813.","DOI":"10.1210\/jc.2005-2813"},{"issue":"3","key":"249_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41433-022-01981-z","volume":"37","author":"H Jeon","year":"2023","unstructured":"Jeon H, Lee JY, Kim YJ, Lee MJ. Clinical relevance of thyroid-stimulating Immunoglobulin as a biomarker of the activity of thyroid eye disease. Eye (London). 2023;37(3):543\u20137. https:\/\/doi.org\/10.1038\/s41433-022-01981-z.","journal-title":"Eye (London)"},{"issue":"2","key":"249_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3341\/kjo.2022.0131","volume":"37","author":"J Malik Moledina","year":"2023","unstructured":"Malik Moledina J, Roos RM. Thyrotropin receptor autoantibody assessment in thyroid eye disease: does the assay type matter?? Korean J Ophthalmol. 2023;37(2):147\u201356. https:\/\/scholar.kyobobook.co.kr\/article\/detail\/4010047343547.","journal-title":"Korean J Ophthalmol"},{"issue":"7","key":"249_CR35","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40618-015-0254-2","volume":"38","author":"KA Ponto","year":"2015","unstructured":"Ponto KA, Diana T, Binder H, Matheis N, Pitz S, Pfeiffer N, et al. Thyroid-stimulating Immunoglobulins indicate the onset of dysthyroid optic neuropathy. J Endocrinol Investig. 2015;38(7):769\u201377. https:\/\/doi.org\/10.1007\/s40618-015-0254-2.","journal-title":"J Endocrinol Investig"},{"issue":"7","key":"249_CR36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1055\/a-1525-2070","volume":"53","author":"M St\u00f6hr","year":"2021","unstructured":"St\u00f6hr M, Oeverhaus M, Lytton SD, Horstmann M, Zwanziger D, M\u00f6ller L, et al. Predicting the course of graves\u2019 orbitopathy using serially measured TSH-Receptor autoantibodies by automated binding immunoassays and the functional bioassay. Horm Metab Res. 2021;53(7):435\u201343. https:\/\/doi.org\/10.1055\/a-1525-2070.","journal-title":"Horm Metab Res"},{"issue":"1","key":"249_CR37","doi-asserted-by":"publisher","first-page":"6259","DOI":"10.1038\/s41598-022-10043-z","volume":"12","author":"M Berger","year":"2022","unstructured":"Berger M, Matlach J, Pitz S, Berres M, Axmacher F, Kahaly GJ, et al. Imaging of the medial rectus muscle predicts the development of optic neuropathy in thyroid eye disease. Sci Rep. 2022;12(1):6259. https:\/\/doi.org\/10.1038\/s41598-022-10043-z.","journal-title":"Sci Rep"},{"key":"249_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2023.11.015","author":"K Rana","year":"2023","unstructured":"Rana K, Garg D, Yong LSS, Macri C, Tong JY, Patel S, et al. Extraocular muscle enlargement in dysthyroid optic neuropathy. Can J Ophthalmol J Canadien D\u2019ophtalmologie. 2023. https:\/\/doi.org\/10.1016\/j.jcjo.2023.11.015.","journal-title":"Can J Ophthalmol J Canadien D\u2019ophtalmologie"},{"issue":"8","key":"249_CR39","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/archopht.1982.01030040244006","volume":"100","author":"SE Feldon","year":"1982","unstructured":"Feldon SE, Weiner JM. Clinical significance of extraocular muscle volumes in graves\u2019 ophthalmopathy: A quantitative computed tomography study. Archives Ophthalmol (1960). 1982;100(8):1266\u20139. https:\/\/doi.org\/10.1001\/archopht.1982.01030040244006.","journal-title":"Archives Ophthalmol (1960)"},{"issue":"5","key":"249_CR40","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1002\/edm2.357","volume":"5","author":"V Uslar","year":"2022","unstructured":"Uslar V, Becker C, Weyhe D, Tabriz N. Thyroid disease-specific quality of life questionnaires \u2010 A systematic review. Endocrinol Diabetes Metabolism. 2022;5(5):e357\u2013na. https:\/\/doi.org\/10.1002\/edm2.357.","journal-title":"Endocrinol Diabetes Metabolism"},{"issue":"7","key":"249_CR41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/bjophthalmol-2020-316433","volume":"105","author":"A Garip-Kuebler","year":"2021","unstructured":"Garip-Kuebler A, Halfter K, Reznicek L, Klingenstein A, Priglinger S, Hintschich CR. Subclinical dysthyroid optic neuropathy: Tritan deficiency as an early sign of dysthyroid optic neuropathy. Br J Ophthalmol. 2021;105(7):1019\u201323. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316433.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"249_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/clinem\/dgad637","volume":"109","author":"RS Douglas","year":"2023","unstructured":"Douglas RS, Couch S, Wester ST, Fowler BT, Liu CY, Subramanian PS, et al. Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab. 2023;109(1):25\u201335. https:\/\/doi.org\/10.1210\/clinem\/dgad637.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"249_CR43","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1089\/thy.2010.1634","volume":"20","author":"MN Stan","year":"2010","unstructured":"Stan MN, Bahn RS. Risk factors for development or deterioration of graves\u2019 ophthalmopathy. Thyroid (New York N Y). 2010;20(7):777\u201383. https:\/\/doi.org\/10.1089\/thy.2010.1634.","journal-title":"Thyroid (New York N Y)"},{"issue":"5","key":"249_CR44","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3341\/kjo.2010.24.5.267","volume":"24","author":"JH Lee","year":"2010","unstructured":"Lee JH, Lee SY, Yoon JS. Risk factors associated with the severity of Thyroid-Associated orbitopathy in Korean patients. Korean J Ophthalmology: KJO. 2010;24(5):267\u201373. https:\/\/doi.org\/10.3341\/kjo.2010.24.5.267.","journal-title":"Korean J Ophthalmology: KJO"},{"key":"249_CR45","doi-asserted-by":"crossref","unstructured":"Cawood TJ, Moriarty P, O\u2019Farrelly C, O\u2019Shea D. Smoking and Thyroid-Associated ophthalmopathy: A novel explanation of the biological link. J Clin Endocrinol Metabolism. 2007;92(1):59\u201364. https:\/\/doi.org\/10.1210\/jc.2006\u20131824.","DOI":"10.1210\/jc.2006-1824"},{"issue":"14","key":"249_CR46","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1001\/archinte.165.14.1606","volume":"165","author":"IA Holm","year":"2005","unstructured":"Holm IA, Manson JE, Michels KB, Alexander EK, Willett WC, Utiger RD. Smoking and other lifestyle factors and the risk of graves\u2019 hyperthyroidism. Archives Intern Med (1960). 2005;165(14):1606\u201311. https:\/\/doi.org\/10.1001\/archinte.165.14.1606.","journal-title":"Archives Intern Med (1960)"},{"issue":"8","key":"249_CR47","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/bjo.2007.137265","volume":"93","author":"AK Eckstein","year":"2009","unstructured":"Eckstein AK, L\u00f6sch C, Glowacka D, Schott M, Mann K, Esser J, et al. Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical graves ophthalmopathy. Br J Ophthalmol. 2009;93(8):1052\u20136. https:\/\/doi.org\/10.1136\/bjo.2007.137265.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"249_CR48","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41433-024-02967-9","volume":"38","author":"M Moledina","year":"2024","unstructured":"Moledina M, Damato EM, Lee V. The changing landscape of thyroid eye disease: current clinical advances and future outlook. Eye (London). 2024;38(8):1425\u201337. https:\/\/doi.org\/10.1038\/s41433-024-02967-9.","journal-title":"Eye (London)"},{"issue":"14","key":"249_CR49","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199104043241403","volume":"324","author":"K Hashizume","year":"1991","unstructured":"Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, et al. Administration of thyroxine in treated graves\u2019 disease. N Engl J Med. 1991;324(14):947\u201353. https:\/\/doi.org\/10.1056\/NEJM199104043241403.","journal-title":"N Engl J Med"},{"issue":"3","key":"249_CR50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/jamaophthalmol.2014.5103","volume":"133","author":"JD Stein","year":"2015","unstructured":"Stein JD, Childers D, Gupta S, Talwar N, Nan B, Lee BJ, et al. Risk factors for developing Thyroid-Associated ophthalmopathy among individuals with graves disease. JAMA Ophthalmol. 2015;133(3):290\u20136. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.5103.","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"249_CR51","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2967\/jnumed.107.049437","volume":"49","author":"JC Sisson","year":"2008","unstructured":"Sisson JC, Schipper MJ, Nelson CC, Freitas JE, Frueh BR. Radioiodine therapy and graves\u2019 ophthalmopathy. J Nucl Med. 2008;49(6):923\u201330. https:\/\/doi.org\/10.2967\/jnumed.107.049437.","journal-title":"J Nucl Med"}],"container-title":["Thyroid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00249-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13044-025-00249-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00249-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:31:27Z","timestamp":1757219487000},"score":1,"resource":{"primary":{"URL":"https:\/\/thyroidresearchjournal.biomedcentral.com\/articles\/10.1186\/s13044-025-00249-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["249"],"URL":"https:\/\/doi.org\/10.1186\/s13044-025-00249-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6284756\/v1","asserted-by":"object"}]},"ISSN":["1756-6614"],"issn-type":[{"value":"1756-6614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional audit department and was conducted by the tenets of the Declaration of Helsinki and all laws in the United Kingdom.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Miss Vickie Lee is the Principal Investigator for the Horizon, Viridian, Lassen and Sling Trials, BOPSS National Lead for Thyroid Eye Disease and has been a consultant for Horizon\/Amgen and Viridian Pharmaceuticals. Mr Malik Moledina is: Sub Investigator for the Viridian, Horizon and Sling Trial. Miss Ourania Fydanaki, Miss Gabriella Guevara & Dr Nour Houbby are Sub Investigators for the Horizon Trial. Dr Claire Feeney is a Pfizer employee in an unrelated field since June 2018. This paper was recently presented at ESOPRS Rotterdam 2024, and formed part of the submission that went on to win the ESOPRS Richard Collins Prize 2024.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}